FDA accepts Kala Pharmaceuticals’ NDA for KPI-121 0.25%

KPI-121 0.25% is designed to provide temporary relief to the signs and symptoms of dry eye disease. Credit: Photo by Daniil Kuželev on Unsplash.



  • FDA